Randomized Trial Comparing PrePex Day 7 Foreskin Removal Procedure (FRP) to a Day 0 PrePex FRP .
NCT ID: NCT03223532
Last Updated: 2019-08-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
152 participants
INTERVENTIONAL
2017-04-26
2017-11-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Circumcision Versus Preputioplasty for BXO in Children
NCT02854995
Phase 4 Field Trial of the Unicirc Instrument With Tissue Adhesive
NCT02091726
Outcome of Plastibell Circumcision Versus Open Method Circumcision
NCT06366984
Fibrin-Enhanced TIP Versus Grafted TIP Urethroplasty in Distal Hypospadias
NCT07319780
Circumcision With a Novel Disposable Device in Chinese Children: a Hospital-based Randomized Controlled Trail
NCT01477593
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
To compare the safety and acceptability of PrePex Day 7 Foreskin Removal Procedure (FRP) (herein: PrePex) versus PrePex Day0 FRP
Planned Subjects Population:
One hundred and fifty (150) subjects scheduled for voluntary medical male circumcision. The subjects will be randomly divided into two unbalanced study arms (2:1), Day0 FRP arm which will include hundred (100) subjects and PrePex arm which will include fifty (50) subjects.
Study duration per subject will be up to 7 weeks and will include a total of 9 visits.
Study Site: University of Nairobi, Illinois, and Manatoba (UNIM) Research and Training Centre, Kisumu, Kenya
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
PrePex Day 7 FRP
Standard PrePex procedure, 1 week after device placement foreskin and device are removed.
\*Subjects must be adequately vaccinated, or willing to be vaccinated, against Tetanus based on appropriate national guidance for male circumcision
PrePex Day 7 FRP
Standard PrePex procedure, foreskin and device are removed 1 week after device application.
PrePex Day 0 FRP
On the day of device placement the foreskin is removed, the device is removed 1 week later.
PrePex Day 0 FRP
Removal of the foreskin shortly after device application, the device is removed 1 week later
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
PrePex Day 7 FRP
Standard PrePex procedure, foreskin and device are removed 1 week after device application.
PrePex Day 0 FRP
Removal of the foreskin shortly after device application, the device is removed 1 week later
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Uncircumcised
* Adequately vaccinated, or willing to be vaccinated, against Tetanus based on appropriate national guidance for male circumcision
* Willing to be circumcised
* Legal guardian consent to the procedure for ages 13-18 years
* Agrees to be circumcised by any of the study methods, Day0 FRP or Day7 FRP as will be determined randomly
* Able to understand the study procedures and requirements
* Agrees to abstain from sexual intercourse for 8 weeks after circumcision
* Agrees to abstain from masturbation for at least 2 weeks after Removal
* Agrees to return to the health care facility for follow-up visits (or as instructed) after his circumcision for a period of 6 weeks post removal (7 weeks total)
* Subject able to comprehend and freely give informed consent for participation in this study and is considered by the investigator to have good compliance for the study
Exclusion Criteria
* Active genital infection, anatomic abnormality or other condition, which in the opinion of the investigator prevents the subject from undergoing a circumcision
* Subject with the following diseases/conditions: phimosis, paraphimosis, adhesions, warts under the prepuce, torn or tight frenulum, narrow prepuce, hypospadias, epispadias
* Known bleeding / coagulation abnormality, uncontrolled diabetes
* Subject that to the opinion of the investigator is not a good candidate
* Subject does not agree to anonymous video and photographs of the procedure and follow up visits.
13 Years
49 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Nyanza Reproductive Health Society
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Fredrick Otieno, M.D.
Role: PRINCIPAL_INVESTIGATOR
Nyanza Reproductive Health Society
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Nyanza Reproductive Health Society
Kisumu, Nyanza, Kenya
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
VMMC005
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.